Coronary artery disease: Dalcetrapib safely raises HDL-cholesterol level in the phase IIb dal-PLAQUE trial

Nature Reviews Cardiology

Volumn 8, Issue 11, 2011, Pages 610-

  Lim, Gregory B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DALCETRAPIB;

ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIDE EFFECT;

EID: 85027956998     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2011.150     Document Type: Note

References (1)

1. Fayad, Z.A. et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodal imaging (dal-PLAQUE): a randomised clinical trial. Lancetdoi:10.1016/S0140-6736(11)61383-4